2-羟基-3-吡啶甲醛 | 36404-89-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-羟基-3-吡啶甲醛
• 中文别名: 2-羟基烟醛；2-氧代-1,2-二氢吡啶-3-甲醛；2-羟基-3-甲酰基吡啶
• 英文名称: 2-hydroxynicotinaldehyde
• 英文别名: 2-hydroxypyridine-3-carbaldehyde；2-oxo-1H-pyridine-3-carbaldehyde
• CAS: 36404-89-4
• 化学式: C₆H₅NO₂
• mdl: MFCD07698588
• 分子量: 123.111
• InChiKey: DNTYEVWEOFZXFE-UHFFFAOYSA-N

物化性质

• 熔点：
  220-222°
• 沸点：
  50 °C(Press: 80 Torr)
• 密度：
  1.365±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S24/25,S26
• 危险类别码：
  R22,R36
• 海关编码：
  2933399090
• WGK Germany：
  3
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Oxo-1,2-dihydro-3-pyridinecarbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Oxo-1,2-dihydro-3-pyridinecarbaldehyde
CAS number: 36404-89-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H5NO2
Molecular weight: 123.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-羟基-3-吡啶甲醛 在 potassium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 反应 8.5h， 生成 ethyl [1-[(1-ethyl-2-oxo-1,2-dihydro-pyridin-3-yl)methylamino]-4-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]acetate
  参考文献：
  名称：

  WO2006/135323

  摘要：

  公开号：
• 作为产物：
  描述：

  2-羟基烟酸 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 乙酸乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 2-羟基-3-吡啶甲醛
  参考文献：
  名称：

  Development of oxathiino[6,5-b]pyridine 2,2-dioxide derivatives as selective inhibitors of tumor-related carbonic anhydrases IX and XII

  摘要：

  Oxathiino[6,5-b]pyridine 2,2-dioxides are identified as a new class of isoform-selective nanomolar inhibitors of tumor associated human carbonic anhydrases (hCA) IX and XII. At the same time they do not inhibit or poorly inhibit cytosolic isoforms hCA I and II. Oxathiino[6,5-b]pyridine 2,2-dioxides exhibited good antiproliferative properties on tumor cell lines MCF-7 (Human breast adenocarcinoma), A549 (human lung (alveolar) adenocarcinoma) and HeLa (epithelioid cervix carcinoma). (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112300
• 作为试剂：
  描述：

  DL-3-甲基天门冬氨酸 在 二(氰基苯)二氯化钯 、 氯化亚砜 、 2-羟基-3-吡啶甲醛 、 palladium diacetate 、 silver trifluoroacetate 作用下， 以 溶剂黄146 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  使用催化瞬变定向基团在游离β2-氨基酯和β3-氨基酯与芳基碘化物之间进行Pd（II）催化的直接γ-C（sp3）-H芳基化反应。

  摘要：

  钯（II）催化的直接γ-C（SP 3）-H芳基化与耦合游离β 2 -氨基酯和β 3个已经开发使用市售的催化瞬态引导组-氨基酯。该方法具有高效，广泛的底物耐受性，易于获得的原料以及温和的反应条件的特点。

  DOI：

  10.1021/acs.joc.0c00115

文献信息

• Novel piperidine compouds and drugs containing the same
  申请人：——

  公开号：US20030220368A1

  公开（公告）日：2003-11-27

  The present invention provides a novel compound having a superior Na + channel inhibition activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. 1 In the formula, the ring A represents a ring represented by the formula: 2 (wherein R 1 represents a hydrogen atom etc.; and R 2 represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C 1-6 alkylene group etc.; Z represents an optionally substituted C 6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.

  本发明提供了一种具有优越的Na + 通道抑制活性的新型化合物。即提供了由以下式（I）表示的化合物，其盐或其水合物。 在该式中，环A表示由以下式表示的环： （其中R 1 表示氢原子等；R 2 表示表示氢原子等）等；W表示可选地取代的C 1-6 烷基等；Z表示可选地取代的C 6-14 芳香烃环基等；l表示0到6的整数。
• Nitrogen containing heterocyclic compounds and medicines containing the same
  申请人：——

  公开号：US20040167224A1

  公开（公告）日：2004-08-26

  Compounds represented by the following general formula: 1 (wherein X 1 , X 2 , X 3 and X 4 each independently represent a single bond, C 1-6 alkylene, etc.; A 2 represents optionally substituted phenyl, etc.; A 1 represents an optionally substituted 5- to 7-membered heterocyclic group containing —C(═Q 1 )— (wherein Q 1 represents oxygen, sulfur or ═N—R 11 (wherein R 11 represents hydrogen or C 1-6 alkyl)) and nitrogen, etc.; and Z 1 represents piperidin-diyl, etc.), salts thereof and hydrates of the foregoing.

  由以下一般式表示的化合物： 1 （其中X 1 、X 2 、X 3 和X 4 分别独立表示单键，C 1-6 烷基等；A 2 表示可选择地取代的苯基等；A 1 表示可选择地取代的含有—C(═Q 1 )—的5-至7-成员杂环基团（其中Q 1 表示氧、硫或═N—R 11 （其中R 11 表示氢或C 1-6 烷基））和氮等；以及Z 1 表示哌啶二基等），以及其盐和上述化合物的水合物。
• [EN] MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS POUR LE RÉCEPTEUR MAS COUPLÉ À LA PROTÉINE G ET TRAITEMENT DES TROUBLES QUI Y SONT APPARENTÉS
  申请人：ARENA PHARM INC

  公开号：WO2013070657A1

  公开（公告）日：2013-05-16

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

  本发明涉及式（I）化合物及其药用可接受的盐、溶剂和水合物，这些化合物在治疗和缓解由缺血引起的心脏、脑、肾脏、免疫系统和生殖系统的疾病和紊乱方面具有用处，或者在缺血后再灌注引起的疾病和障碍，以及与之相关的任何下游并发症。本发明还涉及治疗和缓解由血管收缩或高血压引起的血管疾病和障碍的方法，以及由高血压和/或组织灌注减少引起的任何下游并发症。
• [EN] IMIDAZOTRIAZINONE COMPOUNDS<br/>[FR] COMPOSÉS D'IMIDAZOTRIAZINONE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2013142269A1

  公开（公告）日：2013-09-26

  The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

  本发明提供了咪唑三唑酮化合物，它们是磷酸二酯酶9的抑制剂及其药用盐。本发明还提供了用于治疗哺乳动物，包括人类，PDE9相关疾病或疾病的过程、药物组成、药物制剂和化合物的药用。
• Synthesis of phenanthridine spiropyrans and studies of their effects on G-quadruplex DNA
  作者：M. Livendahl、J. Jamroskovic、M. Hedenström、T. Görlich、N. Sabouri、E. Chorell

  DOI：10.1039/c7ob00300e

  日期：——

  G-quadruplex (G4) DNA structures are involved in many important biological processes and can be linked to several human diseases. Drug-like low molecular weight compounds that target G4 structures are therefore interesting not only for their potential therapeutic properties but also for their potential use as chemical research tools. We report here on the development of methods to synthesize spiropyrans

  G-四链体（G4）DNA结构涉及许多重要的生物学过程，并且可以与多种人类疾病相关。因此，靶向G4结构的类药物低分子量化合物不仅因为其潜在的治疗特性而且还潜在地用作化学研究工具而引起人们的兴趣。我们在这里报告了利用α-甲基喹啉或菲啶的季盐与水杨醛的缩合环化反应合成螺吡喃的方法的发展。用硫黄素T置换试验，圆二色性，Taq DNA聚合酶终止试验和NMR对合成的菲螺螺吡喃与G4 DNA的相互作用进行评估。这表明菲啶螺吡喃上的取代模式对于它们结合和稳定G4结构的能力非常重要。一些合成的低分子量螺环化合物通过将第一个G-tetrad结合到G4结构中，有效地稳定了G4结构，而不会引起结构变化。